PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging.
Avidin/Biotin
Colon cancer
ImmunoPET
PD-L1
Pre-targeting
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
17 09 2023
17 09 2023
Historique:
received:
10
05
2023
revised:
20
05
2023
accepted:
17
06
2023
medline:
1
8
2023
pubmed:
25
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
This study aimed to establish the radio-immune imaging protocol on the basis of Avidin/Biotin system. The programmed death-ligand 1 (PD-L1) antibody (Atezolizumab) was employed as the primary molecule in targeting PD-L1, and the two-step strategy, consisting of the first injection of Avidin-conjugated PD-L1 monoclonal antibody (Atezolizumab) and the second injection of 7.4 MBq
Identifiants
pubmed: 37354656
pii: S0006-291X(23)00814-8
doi: 10.1016/j.bbrc.2023.06.059
pii:
doi:
Substances chimiques
Biotin
6SO6U10H04
Avidin
1405-69-2
CD274 protein, human
0
B7-H1 Antigen
0
Gallium Radioisotopes
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-28Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest. The authors declare no conflict of interest.